The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib

BACKGROUND AND AIMS: The multikinase inhibitor sorafenib is the only currently approved drug for the indication of advanced hepatocellular carcinoma (HCC). It provides a limited gain in survival time but is frequently associated with adverse events. We currently lack simple prognostic factors in sor...

Descripción completa

Detalles Bibliográficos
Autores principales: Conroy, Guillaume, Salleron, Julia, Belle, Arthur, Bensenane, Mouni, Nani, Abdelbasset, Ayav, Ahmet, Peiffert, Didier, Lopez, Anthony, Baumann, Cédric, Barraud, Hélène, Bronowicki, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707066/
https://www.ncbi.nlm.nih.gov/pubmed/29221172
http://dx.doi.org/10.18632/oncotarget.21401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707066/
https://www.ncbi.nlm.nih.gov/pubmed/29221172
http://dx.doi.org/10.18632/oncotarget.21401

Ejemplares similares